Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 CHENXiao-yan ¹ , WANGTing ¹ , TAOZhen-xia ¹ , ZENGXian-tao ^1,2,3 , LISheng ^1,2,3 ,  WENGHong ^1,2,3

1. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;
2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;
3. Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan 430071, China;

Corresponding author：

WENGHong, Email: wengh92@163.com

Keywords：

Prostate cancer; E-cadherin; Chinese people; Disease risk; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20160121

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the correlation between E-cadherin expression and prostate cancer, as well as its clinicopathologic features in Chinese population. Methods Such databases as PubMed, EMbase, CBM, CNKI, VIP and WanFang Data were electronically searched from their inception to December, 2015 to collect case-control studies about the correlation between E-cadherin expression and prostate cancer, as well as its clinically pathologic features in Chinese population. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results A total of 21 studies were included, involving 920 prostate cancer cases, 415 benign prostatic hyperplasia cases, and 48 controls. The results of meta-analysis showed that the prostate cancer group had a lower E-cadherin expression level when compared with the benign prostatic hyperplasia group (OR=0.07, 95%CI 0.05 to 0.11, P<0.00001) or the control group (OR=0.04, 95%CI 0.01 to 0.18, P<0.00001). Moreover, the expression level of E-cadherin was lower in the low and medium differentiation group than in the high differentiation group (OR=0.13, 95%CI 0.08 to 0.23, P<0.00001), lower in the stage of C+D than in the stage of A+B (OR=0.23, 95%CI 0.15 to 0.34, P<0.00001), and lower in the prostate cancer with metastasis (OR=0.46, 95%CI 0.27 to 0.79, P=0.005) and it was decreased gradually with the increment of pathological differentiation and clinical stage of prostate cancer and with the decrement of lymph node or bone metastasis and serum PSA level. Conclusion Current evidence indicates that the expression level of E-cadherin is significantly correlated with prostate cancer and its clinicopathologic features in Chinese population. Due to limited sample size and quality of included studies, the conclusion needs to be verified by conducting more high quality studies.

Citation： CHENXiao-yan, WANGTing, TAOZhen-xia, ZENGXian-tao, LISheng, WENGHong. Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(7): 780-787. doi: 10.7507/1672-2531.20160121 Copy

1.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2.	Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer:weighing the evidence. Eur Urol, 2013, 63(5):800-809.
3.	王行环, 瞿利军. 前列腺癌早期诊断进展. 临床外科杂志, 2006, 14(2):79-81.
4.	刘修恒. 前列腺癌的早期诊断. 临床泌尿外科杂志, 2007, 22(7):482-485.
5.	Hodson R. Prostate cancer:4 big questions. Nature, 2015, 528(7582):S137.
6.	曾宪涛, 冷卫东, 郭毅, 等. Meta分析系列之一:Meta分析的类型. 中国循证心血管医学杂志, 2012, 4(1):3-5.
7.	Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia:evidence from a systematic review and meta-analysis. Sci Rep, 2015, 5:12002.
8.	曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四:观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4):297-299.
9.	Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline:a systematic review. J Evid Based Med, 2015, 8(1):2-10.
10.	曾少波, 阮晓岚, 翁鸿, 等. p63蛋白表达与非小细胞肺癌风险相关性的Meta分析. 湖北医药学院学报, 2015, 34(4):371-376.
11.	Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1559.
12.	黄啸, 周利群, 艾军魁, 等. 前列腺癌E和N型钙粘附素的表达及意义. 癌症, 2002, 21(11):1208-1211.
13.	戚晓平, 钱斌, 林考兴, 等. 前列腺癌组织中ILK和E-Cadherin的表达及其意义. 实用癌症杂志, 2004, 19(5):478-480.
14.	姚青, 穆红, 张建民, 等. 前列腺病变中E-cadherin、p16和ER表达及意义. 临床与实验病理学杂志, 2004, 20(6):698-701.
15.	谷化平, 尚培中, 周翠玲. CD44v6和E-上皮钙黏附素在前列腺癌组织中的表达与癌转移的关系. 中华男科学杂志, 2004, 10(1):32-34.
16.	阎利, 戚晓平, 林孝兴, 等. E-cadherin蛋白在前列腺癌组织中的表达及临床意义. 临床军医杂志, 2004, 23(2):32-34.
17.	何全中. COX-2和E-cadherin在前列腺癌中的表达与意义. 新乡:新乡医学院, 2006.
18.	张锡流, 何仕远, 张力, 等. E-钙黏附蛋白及其相关蛋白在前列腺癌组织中的表达及其临床意义. 检验医学, 2006, 21(1):5-7.
19.	朱煊. 前列腺癌中E钙粘连蛋白和环氧化酶2表达的免疫组化研究. 长沙:中南大学, 2007.
20.	孙明, 潘春雨, 刘学锋, 等. S100A4蛋白和E-cadherin蛋白在前列腺癌中的表达及临床意义. 现代肿瘤医学, 2009, 17(10):1921-1924.
21.	侯铸, 罗勇, 赵佳晖, 等. EMT标记蛋白在前列腺癌组织中的表达及其意义. 中国男科学杂志, 2009, 23(12):21-24.
22.	王霞, 章明放, 张玉洁. 钙黏附蛋白及降钙素在前列腺癌组织中的表达及意义. 山东医药, 2010, 50(43):34-36.
23.	高双友, 宋蕊, 李双利, 等. E-cadherin及sE-cadherin在42例前列腺癌中的表达及意义. 重庆医学, 2010, 39(23):3240-3241.
24.	冀楠. Snail、Slug、E-cadherin在前列腺癌中的表达及其意义. 武汉:武汉科技大学, 2011.
25.	毛洲洲. Survivin和E-Cadherin在前列腺癌中的表达及意义. 湛江:广东医学院, 2011.
26.	胡祥坤, 程帆, 阮远, 等. p130Cas和E-cadherin在前列腺癌组织中的表达及其临床意义. 中华实验外科杂志, 2011, 28(12):2055-2056.
27.	姜涛, 姜辉, 苏晓明, 等. E-cd和α-Cat表达与前深腺组织良恶性和转移性关系的研究. 中华男科学杂志, 2012, 18(6):499-503.
28.	王翔. E-cadherin、TGF-β1及Twist在前列腺癌中的表达及意义. 济南:山东大学, 2013.
29.	温爽, 盖宇, 宗华凤, 等. 前列腺癌组织P504S、E-Cadherin和bcl-2蛋白表达及意义. 大连医科大学学报, 2013, 35(2):25-28.
30.	郭宏涛. E-cadherin和N-cadherin在前列腺癌中的表达及意义. 兰州:兰州大学, 2014.
31.	刘祎, 陈先国, 梁朝朝. 前列腺癌肿瘤组织中E-cadherin和N-cadherin的表达及意义. 中华男科学杂志, 2014, 20(9):781-786.
32.	韩丽媛, 王伟, 王慧萍, 等. 前列腺癌组织中p53、bcl-2和E-cadherin蛋白的表达水平及临床意义. 生殖医学杂志, 2015, 24(10):845-849.
33.	Masterson J, O'Dea S. Posttranslational truncation of E-cadherin and significance for tumour progression. Cells Tissues Organs, 2007, 185(1-3):175-179.
34.	Halbleib JM, Nelson WJ. Cadherins in development:cell adhesion, sorting, and tissue morphogenesis. Genes Dev, 2006, 20(23):3199-3214.
35.	石珍亮, 张逊. E-cadherin黏附系统及其与肿瘤侵袭转移的关系. 天津医药, 2008, 36(6):476-478.
36.	Gould RB, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast:a systematic review and meta-analysis. Breast Cancer Res Treat, 2006, 100(2):139-148.
37.	那彦群, 叶章群, 孙颖浩, 等. 中国临床泌尿外科疾病诊断治疗指南. 北京:人民卫生出版社, 2013.

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer:weighing the evidence. Eur Urol, 2013, 63(5):800-809.
3. 王行环, 瞿利军. 前列腺癌早期诊断进展. 临床外科杂志, 2006, 14(2):79-81.
4. 刘修恒. 前列腺癌的早期诊断. 临床泌尿外科杂志, 2007, 22(7):482-485.
5. Hodson R. Prostate cancer:4 big questions. Nature, 2015, 528(7582):S137.
6. 曾宪涛, 冷卫东, 郭毅, 等. Meta分析系列之一:Meta分析的类型. 中国循证心血管医学杂志, 2012, 4(1):3-5.
7. Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia:evidence from a systematic review and meta-analysis. Sci Rep, 2015, 5:12002.
8. 曾宪涛, 刘慧, 陈曦, 等. Meta分析系列之四:观察性研究的质量评价工具. 中国循证心血管医学杂志, 2012, 4(4):297-299.
9. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline:a systematic review. J Evid Based Med, 2015, 8(1):2-10.
10. 曾少波, 阮晓岚, 翁鸿, 等. p63蛋白表达与非小细胞肺癌风险相关性的Meta分析. 湖北医药学院学报, 2015, 34(4):371-376.
11. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1559.
12. 黄啸, 周利群, 艾军魁, 等. 前列腺癌E和N型钙粘附素的表达及意义. 癌症, 2002, 21(11):1208-1211.
13. 戚晓平, 钱斌, 林考兴, 等. 前列腺癌组织中ILK和E-Cadherin的表达及其意义. 实用癌症杂志, 2004, 19(5):478-480.
14. 姚青, 穆红, 张建民, 等. 前列腺病变中E-cadherin、p16和ER表达及意义. 临床与实验病理学杂志, 2004, 20(6):698-701.
15. 谷化平, 尚培中, 周翠玲. CD44v6和E-上皮钙黏附素在前列腺癌组织中的表达与癌转移的关系. 中华男科学杂志, 2004, 10(1):32-34.
16. 阎利, 戚晓平, 林孝兴, 等. E-cadherin蛋白在前列腺癌组织中的表达及临床意义. 临床军医杂志, 2004, 23(2):32-34.
17. 何全中. COX-2和E-cadherin在前列腺癌中的表达与意义. 新乡:新乡医学院, 2006.
18. 张锡流, 何仕远, 张力, 等. E-钙黏附蛋白及其相关蛋白在前列腺癌组织中的表达及其临床意义. 检验医学, 2006, 21(1):5-7.
19. 朱煊. 前列腺癌中E钙粘连蛋白和环氧化酶2表达的免疫组化研究. 长沙:中南大学, 2007.
20. 孙明, 潘春雨, 刘学锋, 等. S100A4蛋白和E-cadherin蛋白在前列腺癌中的表达及临床意义. 现代肿瘤医学, 2009, 17(10):1921-1924.
21. 侯铸, 罗勇, 赵佳晖, 等. EMT标记蛋白在前列腺癌组织中的表达及其意义. 中国男科学杂志, 2009, 23(12):21-24.
22. 王霞, 章明放, 张玉洁. 钙黏附蛋白及降钙素在前列腺癌组织中的表达及意义. 山东医药, 2010, 50(43):34-36.
23. 高双友, 宋蕊, 李双利, 等. E-cadherin及sE-cadherin在42例前列腺癌中的表达及意义. 重庆医学, 2010, 39(23):3240-3241.
24. 冀楠. Snail、Slug、E-cadherin在前列腺癌中的表达及其意义. 武汉:武汉科技大学, 2011.
25. 毛洲洲. Survivin和E-Cadherin在前列腺癌中的表达及意义. 湛江:广东医学院, 2011.
26. 胡祥坤, 程帆, 阮远, 等. p130Cas和E-cadherin在前列腺癌组织中的表达及其临床意义. 中华实验外科杂志, 2011, 28(12):2055-2056.
27. 姜涛, 姜辉, 苏晓明, 等. E-cd和α-Cat表达与前深腺组织良恶性和转移性关系的研究. 中华男科学杂志, 2012, 18(6):499-503.
28. 王翔. E-cadherin、TGF-β1及Twist在前列腺癌中的表达及意义. 济南:山东大学, 2013.
29. 温爽, 盖宇, 宗华凤, 等. 前列腺癌组织P504S、E-Cadherin和bcl-2蛋白表达及意义. 大连医科大学学报, 2013, 35(2):25-28.
30. 郭宏涛. E-cadherin和N-cadherin在前列腺癌中的表达及意义. 兰州:兰州大学, 2014.
31. 刘祎, 陈先国, 梁朝朝. 前列腺癌肿瘤组织中E-cadherin和N-cadherin的表达及意义. 中华男科学杂志, 2014, 20(9):781-786.
32. 韩丽媛, 王伟, 王慧萍, 等. 前列腺癌组织中p53、bcl-2和E-cadherin蛋白的表达水平及临床意义. 生殖医学杂志, 2015, 24(10):845-849.
33. Masterson J, O'Dea S. Posttranslational truncation of E-cadherin and significance for tumour progression. Cells Tissues Organs, 2007, 185(1-3):175-179.
34. Halbleib JM, Nelson WJ. Cadherins in development:cell adhesion, sorting, and tissue morphogenesis. Genes Dev, 2006, 20(23):3199-3214.
35. 石珍亮, 张逊. E-cadherin黏附系统及其与肿瘤侵袭转移的关系. 天津医药, 2008, 36(6):476-478.
36. Gould RB, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast:a systematic review and meta-analysis. Breast Cancer Res Treat, 2006, 100(2):139-148.
37. 那彦群, 叶章群, 孙颖浩, 等. 中国临床泌尿外科疾病诊断治疗指南. 北京:人民卫生出版社, 2013.

Chinese Journal of Evidence-Based Medicine

Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content